Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TODORA: Concentration-guided Tocilizumab Dose Reduction in RA
NCT03895879Phase 4Recruiting
- Sponsor
- Reade Rheumatology Research Institute
- Start
- Mar 2020
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Reade Rheumatology Research Institute. Primary endpoint: Disease Activity Score in 28 joints using Erythrocyte Sedimentation Rate at 28 weeks. Started Mar 2020; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03895879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895879.